First Citizens Bank & Trust Co. Has $615,000 Position in Axon Enterprise, Inc. (NASDAQ:AXON)

First Citizens Bank & Trust Co. reduced its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 5.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,539 shares of the biotechnology company’s stock after selling 94 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Axon Enterprise were worth $615,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Mather Group LLC. grew its position in shares of Axon Enterprise by 3.7% during the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock worth $303,000 after buying an additional 27 shares during the period. CWM LLC lifted its holdings in shares of Axon Enterprise by 1.3% during the 3rd quarter. CWM LLC now owns 2,856 shares of the biotechnology company’s stock valued at $1,141,000 after purchasing an additional 36 shares in the last quarter. SPC Financial Inc. lifted its holdings in shares of Axon Enterprise by 2.2% during the 3rd quarter. SPC Financial Inc. now owns 1,773 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 38 shares in the last quarter. Dorsey Wright & Associates lifted its holdings in shares of Axon Enterprise by 0.3% during the 2nd quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company’s stock valued at $4,135,000 after purchasing an additional 39 shares in the last quarter. Finally, Avantax Advisory Services Inc. lifted its holdings in shares of Axon Enterprise by 0.8% during the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after purchasing an additional 40 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Trading Up 0.8 %

Shares of Axon Enterprise stock opened at $438.05 on Monday. Axon Enterprise, Inc. has a 12-month low of $199.29 and a 12-month high of $440.89. The stock has a market cap of $33.10 billion, a P/E ratio of 115.58, a P/E/G ratio of 11.74 and a beta of 0.94. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. The business’s 50 day moving average is $388.71 and its 200-day moving average is $331.79.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The company had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business’s revenue was up 34.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.80 EPS. Equities research analysts predict that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Michael Garnreiter sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total transaction of $437,980.00. Following the transaction, the director now directly owns 26,259 shares of the company’s stock, valued at approximately $11,500,916.82. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Patrick W. Smith sold 80,300 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the transaction, the chief executive officer now directly owns 3,015,366 shares of the company’s stock, valued at approximately $1,121,052,771.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the transaction, the director now directly owns 26,259 shares in the company, valued at $11,500,916.82. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 371,172 shares of company stock valued at $137,000,162. 6.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on AXON shares. Craig Hallum lifted their price objective on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group started coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $400.00 target price on shares of Axon Enterprise in a research note on Wednesday, August 7th. Northland Securities boosted their target price on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Finally, Robert W. Baird boosted their target price on Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.